FTH: Analyst Conviction Meets a Short Book That Won't Quit

The Street, by contrast, is almost uniformly bullish. Eleven analysts carry Buy-equivalent ratings with no holds or sells on the register. Guggenheim initiated on September 16 with a $70 target — the highest on the Street — while Lucid Capital Markets added a $59 target two days earlier. TD Cowen also initiated with a Buy earlier in the month. The consensus mean target of $56.67 implies roughly 64% upside from the current $34.50 close, a gap that reflects genuine optimism around Piktor, the company's lead oncology candidate in Phase 2 for breast and endometrial cancer. Bulls point to improving tolerability data and institutional partnership quality. Bears flag the single-arm Phase 2 design as a structural risk, competition in the cancer space, and a valuation that is hard to anchor given deeply negative earnings — the trailing PE sits at -4.9 and EV/EBITDA at -6.0, both normal for a pre-revenue biotech but uncomfortable if Piktor hits a setback. The analyst recommendation factor ranks in the 99th percentile versus the broad universe, meaning the degree of bullish consensus here is near-unprecedented relative to peers.

Institutional ownership adds an interesting layer. The top-holder register reads like a specialist biotech fund lineup: Khosla Ventures at 10.2%, S2G Investments at 9.99%, Suvretta Capital Management at 7.8%, Baker Bros. at nearly 5%, and Avoro Capital at 5.6%. Most of these positions were reported as entirely new in June and July filings — this is a shareholder base that largely assembled itself during and after the IPO wave, not one that has been accumulating quietly over years. ICS Opportunities cut its stake from 9.6% to 3.1% by early June, and StemPoint Capital exited entirely by August, filing a 13G/A showing zero shares. Caligan Partners similarly trimmed from 9.4% to 2.4%. The exits are notable — three separate sub-5% crossings within a few months of the stock's listing — though all three used the passive 13G form, suggesting these were position-sizing decisions rather than activist disengagement. The CFO, Brian Stephenson, bought roughly $481,000 in open-market shares across multiple tranches in late June at prices between $22.95 and $26.39, with no 10b5-1 plan in place. Those purchases now sit at roughly a 30% gain. The buying was discretionary and clustered — a signal worth noting even if the dollar amount is modest relative to institutional flows.

Earnings history adds texture to the risk calendar. The next print is scheduled for November 12. The prior four reports all saw the stock fall on the day — down 10%, down 14.6%, down 6.2%, and a brief recovery of 2.8% — but five-day returns after each event were sharply positive, ranging from 9.7% to 31.8%. The pattern suggests that initial reactions to Faeth results have been negative, only to reverse as investors digest the clinical read-throughs. Whether that pattern holds for a stock now trading at $34.50 against a float where shorts have stacked up well beyond 100% is the question. Peer names TYRA gained 16.8% on the week and ACRV fell 7.5%, illustrating how binary small-cap biotech moves remain across this cohort.

The next inflection to watch is whether availability continues to compress toward the 52-week low of 0.5% — at that point the borrow market would effectively close to new entrants — or whether the current tightening stabilises, giving the short book room to build further ahead of the November earnings date.